BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 25655613)

  • 1. Treatment strategies in mantle cell lymphoma.
    Maddocks K; Blum KA
    Cancer Treat Res; 2015; 165():251-70. PubMed ID: 25655613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2015 Aug; 90(8):739-45. PubMed ID: 26103436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
    William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is hematopoietic cell transplantation still a valid option for mantle cell lymphoma in first remission in the chemoimmunotherapy-era?
    Chaudhary L; Kharfan-Dabaja MA; Hari P; Hamadani M
    Bone Marrow Transplant; 2013 Nov; 48(12):1489-96. PubMed ID: 23584438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2013 Dec; 88(12):1082-8. PubMed ID: 24273091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
    Dawar R; Hernandez-Ilizaliturri F
    Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2012 Jun; 87(6):604-9. PubMed ID: 22615102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies on Current Practice.
    Avivi I; Goy A
    Clin Cancer Res; 2015 Sep; 21(17):3853-61. PubMed ID: 26059189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unmet needs in the treatment of mantle cell lymphoma.
    Rosen ST; Link BK; Fowler NH
    Clin Adv Hematol Oncol; 2013 Nov; 11(11 Suppl 18):1-19. PubMed ID: 24893041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current regimens and novel agents for mantle cell lymphoma.
    Chen Y; Wang M; Romaguera J
    Br J Haematol; 2014 Oct; 167(1):3-18. PubMed ID: 24974852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mantle Cell Lymphoma: First-line Therapy in Patients Not Eligible for Stem Cell Transplantation.
    Nazeef M; Kahl BS
    Curr Treat Options Oncol; 2015 Jun; 16(6):29. PubMed ID: 25975443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Current strategies in the treatment of advanced stage mantle cell lymphoma].
    Lenz G; Dreyling M; Unterhalt M; Hiddemann W
    Dtsch Med Wochenschr; 2004 Nov; 129(45):2429-33. PubMed ID: 15529247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease.
    Tarockoff M; Gonzalez T; Ivanov S; Sandoval-Sus J
    Curr Oncol Rep; 2022 Oct; 24(10):1313-1326. PubMed ID: 35639332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current treatment strategy in mantle cell lymphoma].
    Ogura M
    Nihon Rinsho; 2014 Mar; 72(3):499-511. PubMed ID: 24724411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma.
    Andersen NS; Pedersen LB; Laurell A; Elonen E; Kolstad A; Boesen AM; Pedersen LM; Lauritzsen GF; Ekanger R; Nilsson-Ehle H; Nordström M; Fredén S; Jerkeman M; Eriksson M; Väärt J; Malmer B; Geisler CH
    J Clin Oncol; 2009 Sep; 27(26):4365-70. PubMed ID: 19652064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrating emerging treatment options in mantle cell lymphoma.
    Kahl BS; Fowler NH; Czuczman MS
    Clin Adv Hematol Oncol; 2013 Dec; 11(12 Suppl 19):1-15. PubMed ID: 24893155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mantle cell lymphoma: Towards a personalized therapeutic strategy?].
    Navarro Matilla B; García-Marco JA
    Med Clin (Barc); 2015 Jun; 144(12):553-9. PubMed ID: 25023849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mantle Cell Lymphoma -  Cutting edge Dia-gnostics and Treatment Approaches].
    Klener P; Trněný M
    Klin Onkol; 2015; 28 Suppl 3():3S80-6. PubMed ID: 26489506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolving treatment strategies in mantle cell lymphoma.
    Edwin NC; Kahl B
    Best Pract Res Clin Haematol; 2018 Sep; 31(3):270-278. PubMed ID: 30213396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.